{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:26:13Z","timestamp":1795029973036,"version":"4.10.2"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-026-02350-x","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:37:13Z","timestamp":1776418633000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sex-specific management of migraine a systematic review and consensus statement from the European Headache Federation (EHF)"],"prefix":"10.1186","volume":"27","author":[{"given":"Simone","family":"Braca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Casillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esme","family":"Ekizoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte-Helene","family":"Bjork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Szewczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Van Dycke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Uluduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Deligianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erling","family":"Tronvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal Mohammad","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Versijpt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Ryli\u0161kien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita Sanchez del","family":"Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil R.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Terwindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"MaassenVanDenBrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4256-4256","authenticated-orcid":false,"given":"Raquel","family":"Gil-Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"1","key":"2350_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s10194-025-02192-z","volume":"26","author":"AK Hus\u00f8y","year":"2025","unstructured":"Hus\u00f8y AK, Steiner TJ (2025) GBD 2023: over twice the health loss from headache disorders among females compared with males, and one fifth of the loss is attributable to medication overuse. J Headache Pain 26(1):227","journal-title":"J Headache Pain"},{"issue":"10283","key":"2350_CR2","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Terwindt GM, Al-Karagholi MA, de Boer I, Lee MJ, Hay DL et al (2021) Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397(10283):1496\u20131504","journal-title":"Lancet"},{"issue":"1","key":"2350_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1474-4422(16)30293-9","volume":"16","author":"KG Vetvik","year":"2017","unstructured":"Vetvik KG, MacGregor EA (2017) Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol 16(1):76\u201387","journal-title":"The Lancet Neurol"},{"key":"2350_CR4","doi-asserted-by":"publisher","first-page":"549038","DOI":"10.3389\/fneur.2020.549038","volume":"11","author":"L Al-Hassany","year":"2020","unstructured":"Al-Hassany L, Haas J, Piccininni M, Kurth T, Maassen Van Den Brink A, Rohmann JL (2020) Giving researchers a Headache - sex and gender differences in migraine. Front Neurol 11:549038","journal-title":"Front Neurol"},{"issue":"1","key":"2350_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s10194-024-01771-w","volume":"25","author":"S Singh","year":"2024","unstructured":"Singh S, Kopruszinski CM, Watanabe M, Dodick DW, Navratilova E, Porreca F (2024) Female-selective mechanisms promoting migraine. J Headache Pain 25(1):63","journal-title":"J Headache Pain"},{"issue":"1","key":"2350_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s10194-024-01893-1","volume":"25","author":"A Maddahi","year":"2024","unstructured":"Maddahi A, Edvinsson JCA, Edvinsson L (2024) Sex differences in expression of CGRP family of receptors and ligands in the rat trigeminal system. J Headache Pain 25(1):193","journal-title":"J Headache Pain"},{"issue":"1","key":"2350_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s10194-025-02071-7","volume":"26","author":"A Holm","year":"2025","unstructured":"Holm A, Edvinsson JCA, Krause DN, Edvinsson L (2025) RAMP1-dependent hormonal regulation of CGRP and its receptor in the trigeminal ganglion. J Headache Pain 26(1):142","journal-title":"J Headache Pain"},{"issue":"1","key":"2350_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s10194-025-01966-9","volume":"26","author":"G Krivoshein","year":"2025","unstructured":"Krivoshein G, Rivera-Mancilla E, MaassenVandenbrink A, Giniatullin R, van den Maagdenberg A (2025) Sex difference in TRPM3 channel functioning in nociceptive and vascular systems: an emerging target for migraine therapy in females? J Headache Pain 26(1):40","journal-title":"J Headache Pain"},{"issue":"2","key":"2350_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1212\/WNL.0000000000001142","volume":"84","author":"K Ibrahimi","year":"2015","unstructured":"Ibrahimi K, van Oosterhout WP, van Dorp W, Danser AH, Garrelds IM, Kushner SA et al (2015) Reduced trigeminovascular cyclicity in patients with menstrually related migraine. Neurology 84(2):125\u2013131","journal-title":"Neurology"},{"issue":"9","key":"2350_CR10","doi-asserted-by":"publisher","first-page":"333102424128149","DOI":"10.1177\/03331024241281493","volume":"44","author":"CM Kopruszinski","year":"2024","unstructured":"Kopruszinski CM, Lee G, Martin LK, Barber KR, Moutal A, Dodick DW et al (2024) A male-specific mechanism of meningeal nociceptor sensitization promoting migraine headache. Cephalalgia 44(9):3331024241281493","journal-title":"Cephalalgia"},{"issue":"1","key":"2350_CR11","first-page":"99","volume":"119","author":"K Eikermann-Haerter","year":"2009","unstructured":"Eikermann-Haerter K, Dilek\u00f6z E, Kudo C, Savitz SI, Waeber C, Baum MJ et al (2009) Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. J Clin Invest 119(1):99\u2013109","journal-title":"J. Clin. Invest"},{"issue":"10","key":"2350_CR12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41582-021-00544-2","volume":"17","author":"DN Krause","year":"2021","unstructured":"Krause DN, Warfvinge K, Haanes KA, Edvinsson L (2021) Hormonal influences in migraine - interactions of oestrogen, oxytocin and CGRP. Nat Rev Neurol 17(10):621\u2013633","journal-title":"Nat Rev Neurol"},{"issue":"69","key":"2350_CR13","doi-asserted-by":"publisher","first-page":"114109","DOI":"10.18632\/oncotarget.23141","volume":"8","author":"AJ Sandweiss","year":"2017","unstructured":"Sandweiss AJ, Cottier KE, McIntosh MI, Dussor G, Davis TP, Vanderah TW et al (2017) 17-\u03b2-estradiol induces spreading depression and pain behavior in alert female rats. Oncotarget 8(69):114109\u2013114122","journal-title":"Oncotarget"},{"issue":"5","key":"2350_CR14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S0896-6273(04)00085-6","volume":"41","author":"van den Maagdenberg Am","year":"2004","unstructured":"van den Maagdenberg Am, Pietrobon D, Pizzorusso T, Kaja S, Broos LA, Cesetti T et al (2004) A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron 41(5):701\u2013710","journal-title":"Neuron"},{"issue":"1","key":"2350_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.nbd.2006.08.013","volume":"25","author":"M Sachs","year":"2007","unstructured":"Sachs M, Pape HC, Speckmann EJ, Gorji A (2007) The effect of estrogen and progesterone on spreading depression in rat neocortical tissues. Neurobiol Dis 25(1):27\u201334","journal-title":"Neurobiol Dis"},{"issue":"6","key":"2350_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ana.21138","volume":"61","author":"KC Brennan","year":"2007","unstructured":"Brennan KC, Romero Reyes M, L\u00f3pez Vald\u00e9s HE, Arnold AP, Charles AC (2007) Reduced threshold for cortical spreading depression in female mice. Ann Neurol 61(6):603\u2013606","journal-title":"Ann Neurol"},{"issue":"11","key":"2350_CR17","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1111\/bph.17472","volume":"182","author":"E Rivera-Mancilla","year":"2025","unstructured":"Rivera-Mancilla E, Musterd-Bhaggoe UM, Schutter D, van den Bogaerdt A, Vincent A, Villal\u00f3n CM et al (2025) Sex differences in the vasoactive effect of transient receptor potential channels: TRPM3 as a new therapeutic target for (neuro)vascular disorders. Br J Pharmacol 182(11):2503\u20132523","journal-title":"Br J Pharmacol"},{"issue":"7","key":"2350_CR18","doi-asserted-by":"publisher","first-page":"333102424125408","DOI":"10.1177\/03331024241254088","volume":"44","author":"de Vries T","year":"2024","unstructured":"de Vries T, Boucherie DM, Chan KY, Rubio-Beltr\u00e1n, Labastida-Ram\u00edrez, Labruijere S et al (2024) Sex differences in CGRP-induced vasodilation of human middle meningeal arteries but not human coronary arteries: implications for migraine. Cephalalgia 44(7):3331024241254088","journal-title":"Cephalalgia"},{"issue":"3","key":"2350_CR19","doi-asserted-by":"publisher","first-page":"333102424123815","DOI":"10.1177\/03331024241238153","volume":"44","author":"F Porreca","year":"2024","unstructured":"Porreca F, Navratilova E, Hirman J, van den Brink AM, Lipton RB, Dodick DW (2024) Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia 44(3):3331024241238153","journal-title":"Cephalalgia"},{"issue":"4","key":"2350_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1212\/WNL.0000000000011216","volume":"96","author":"DS van Casteren","year":"2021","unstructured":"van Casteren, DS, Kurth T, Danser AHJ, Terwindt GM, MaassenVandenbrink A (2021) Sex differences in response to triptans: a systematic review and meta-analysis. Neurology 96(4):162\u2013170","journal-title":"Neurology"},{"issue":"8","key":"2350_CR21","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/head.14944","volume":"65","author":"E Trov\u00e3o Diniz","year":"2025","unstructured":"Trov\u00e3o DinizE, Rocha Leite JB, Ribeiro Coutinho Madruga C, Maia Arca V, Macedo Cavalcanti Albuquerque JA, Sampaio Rocha-Filho PA (2025) Headache in transgender men using gender-affirming hormone therapy: a case-control study. Headache 65(8):1449\u20131456","journal-title":"Headache"},{"key":"2350_CR22","doi-asserted-by":"crossref","unstructured":"Zavala LJ, Gil Ramirez A, Vetvik KG, Jensen RH, Hougaard A (2025) Headache in individuals undergoing hormone therapy for gender transition: a cross-sectional, observational study. Headache","DOI":"10.1111\/head.15076"},{"issue":"7","key":"2350_CR23","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/head.14171","volume":"61","author":"JA Hranilovich","year":"2021","unstructured":"Hranilovich JA, Kaiser EA, Pace A, Barber M, Ziplow J (2021) Headache in transgender and gender-diverse patients: a narrative review. Headache 61(7):1040\u20131050","journal-title":"Headache"},{"issue":"4","key":"2350_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/head.14493","volume":"63","author":"JA Hranilovich","year":"2023","unstructured":"Hranilovich JA, Millington K (2023) Headache prevalence in transgender and gender diverse youth: a single-center case-control study. Headache 63(4):517\u2013522","journal-title":"Headache"},{"issue":"12","key":"2350_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11916-021-00996-7","volume":"25","author":"A Pace","year":"2021","unstructured":"Pace A, Barber M, Ziplow J, Hranilovich JA, Kaiser EA (2021) Gender minority stress, psychiatric comorbidities, and the experience of migraine in transgender and gender-diverse individuals: a narrative review. Curr Pain Headache Rep 25(12):82","journal-title":"Curr Pain Headache Rep"},{"key":"2350_CR26","doi-asserted-by":"crossref","unstructured":"Rosendale N, Guterman EL, Obedin-Maliver J, Flentje A, Capriotti MR, Lubensky ME et al (2022) Migraine, migraine disability, trauma, and discrimination in sexual and gender minority individuals. Neurology 99(14):e1549\u2013e59","DOI":"10.1212\/WNL.0000000000200941"},{"key":"2350_CR27","doi-asserted-by":"publisher","first-page":"1320791","DOI":"10.3389\/fneur.2024.1320791","volume":"15","author":"CI Martinez","year":"2024","unstructured":"Martinez CI, Liktor-Busa E, Largent-Milnes TM (2024) Problems in management of medication overuse headache in transgender and gender non-conforming populations. Front Neurol 15:1320791","journal-title":"Front Neurol"},{"issue":"8","key":"2350_CR28","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/head.14203","volume":"61","author":"P Yalinay Dikmen","year":"2021","unstructured":"Yalinay Dikmen P, Ertas M, Kosak S, Cimentepe C, Kocoglu M, Oztosun G et al (2021) Primary headaches among gender dysphoric female-to-male individuals: a cross-sectional survey on gender transition experience. Headache 61(8):1194\u20131206","journal-title":"Headache"},{"issue":"1","key":"2350_CR29","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5(1):210","journal-title":"Syst Rev"},{"issue":"7650","key":"2350_CR30","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"issue":"4","key":"2350_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J et al (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401\u2013406","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2350_CR32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"IR Diamond","year":"2014","unstructured":"Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM et al (2014) Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 67(4):401\u2013409","journal-title":"J Clin Epidemiol"},{"key":"2350_CR33","doi-asserted-by":"crossref","unstructured":"Gattrell WT, Logullo P, van Zuuren EJ, Price A, Hughes EL, Blazey P et al (2024) ACCORD (ACcurate COnsensus reporting document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi. PLoS Med 21(1):e1004326","DOI":"10.1371\/journal.pmed.1004326"},{"key":"2350_CR34","doi-asserted-by":"crossref","unstructured":"van Zuuren, EJ, Logullo P, Price A, Fedorowicz Z, Hughes EL, Gattrell WT (2022) Existing guidance on reporting of consensus methodology: a systematic review to inform ACCORD guideline development. BMJ Open 12(9):e065154","DOI":"10.1136\/bmjopen-2022-065154"},{"issue":"2","key":"2350_CR35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1177\/0333102418786266","volume":"39","author":"AI Scher","year":"2019","unstructured":"Scher AI, Wang SJ, Katsarava Z, Buse DC, Fanning KM, Adams AM et al (2019) Epidemiology of migraine in men: results from the chronic migraine epidemiology and outcomes (CaMEO) study. Cephalalgia 39(2):296\u2013305","journal-title":"Cephalalgia"},{"issue":"2","key":"2350_CR36","doi-asserted-by":"publisher","first-page":"333102425132061","DOI":"10.1177\/03331024251320610","volume":"45","author":"PJ Goadsby","year":"2025","unstructured":"Goadsby PJ, J\u00fcrgens TP, Brand-Schieber E, Nagy K, Liu Y, Boinpally R et al (2025) Efficacy of ubrogepant and atogepant in males and females with migraine: a secondary analysis of randomized clinical trials. Cephalalgia 45(2):3331024251320610","journal-title":"Cephalalgia"},{"issue":"1","key":"2350_CR37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s10194-021-01336-1","volume":"22","author":"A MaassenVandenbrink","year":"2021","unstructured":"MaassenVandenbrink A, Terwindt GM, Cohen JM, Barash S, Campos VR, Galic M et al (2021) Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study. J Headache Pain 22(1):152","journal-title":"J Headache Pain"},{"key":"2350_CR38","doi-asserted-by":"publisher","first-page":"774341","DOI":"10.3389\/fneur.2021.774341","volume":"12","author":"R Ornello","year":"2021","unstructured":"Ornello R, Baraldi C, Guerzoni S, Lambru G, Fuccaro M, Raffaelli B et al (2021) Gender differences in 3-month outcomes of erenumab treatment-study on efficacy and safety of treatment with erenumab in men. Front Neurol 12:774341","journal-title":"Front Neurol"},{"issue":"3","key":"2350_CR39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.clinthera.2022.01.006","volume":"44","author":"V Martin","year":"2022","unstructured":"Martin V, Nagy AJ, Janelidze M, Giorgadze G, Hirman J, Cady R et al (2022) Impact of baseline characteristics on the efficacy and safety of eptinezumab in patients with migraine: subgroup analyses of PROMISE-1 and PROMISE-2. Clin Ther 44(3):389\u2013402","journal-title":"Clin Ther"},{"issue":"5","key":"2350_CR40","doi-asserted-by":"publisher","first-page":"333102423117080","DOI":"10.1177\/03331024231170807","volume":"43","author":"M Ashina","year":"2023","unstructured":"Ashina M, Lanteri-Minet M, Ettrup A, Christoffersen CL, Josiassen MK, Phul R et al (2023) Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study. Cephalalgia 43(5):3331024231170807","journal-title":"Cephalalgia"},{"issue":"1","key":"2350_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s10194-024-01848-6","volume":"25","author":"CC Khoo","year":"2024","unstructured":"Khoo CC, Liu CC, Lu M, Huang YC, Weng HY (2024) Acute and preventive treatment of menstrual migraine: a meta-analysis. J Headache Pain 25(1):143","journal-title":"J Headache Pain"},{"issue":"1","key":"2350_CR42","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12883-025-04070-2","volume":"25","author":"G Cetin","year":"2025","unstructured":"Cetin G, Totuk O, Cetin OE, Demir S, Sahin S (2025) Evaluation of the effectiveness of greater occipital nerve blockade in menstrual migraine. BMC Neurol 25(1):62","journal-title":"BMC Neurol"},{"issue":"2","key":"2350_CR43","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s40122-021-00273-w","volume":"10","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, Orologio I, Bonavita S, Scotto di Clemente F, Fasano C, Tessitore A et al (2021) Effectiveness and safety of CGRP-mAbs in menstrual-related migraine: a real-world experience. Pain Ther 10(2):1203\u20131214","journal-title":"Pain Ther"},{"issue":"2","key":"2350_CR44","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0333102410378049","volume":"31","author":"G Allais","year":"2011","unstructured":"Allais G, Sanchez Del Rio M, Diener HC, Benedetto C, Pfeil J, Sch\u00e4uble B et al (2011) Perimenstrual migraines and their response to preventive therapy with topiramate. Cephalalgia 31(2):152\u2013160","journal-title":"Cephalalgia"},{"issue":"7","key":"2350_CR45","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1111\/ene.15794","volume":"30","author":"IE Verhagen","year":"2023","unstructured":"Verhagen IE, de Vries Lentsch S, van der Arend BWH, le Cessie S, MaassenVandenbrink A, Terwindt GM (2023) Both perimenstrual and nonperimenstrual migraine days respond to anti-calcitonin gene-related peptide (receptor) antibodies. Eur J Neurol 30(7):2117\u20132121","journal-title":"Eur J Neurol"},{"issue":"6","key":"2350_CR46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0753-3322(02)00181-6","volume":"56","author":"BE Burke","year":"2002","unstructured":"Burke BE, Olson RD, Cusack BJ (2002) Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine. Biomed Pharmacother 56(6):283\u2013288","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2350_CR47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1046\/j.1526-4610.2000.00003.x","volume":"40","author":"C Olesen","year":"2000","unstructured":"Olesen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J (2000) Pregnancy outcome following prescription for sumatriptan. Headache 40(1):20\u201324","journal-title":"Headache"},{"issue":"4","key":"2350_CR48","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1046\/j.1526-4610.2001.111006351.x","volume":"41","author":"B K\u00e4ll\u00e9n","year":"2001","unstructured":"K\u00e4ll\u00e9n B, Lygner PE (2001) Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 41(4):351\u2013356","journal-title":"Headache"},{"issue":"4","key":"2350_CR49","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1526-4610.2010.01619.x","volume":"50","author":"K Nezvalov\u00e1-Henriksen","year":"2010","unstructured":"Nezvalov\u00e1-Henriksen K, Spigset O, Nordeng H (2010) Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian mother and child cohort study. Headache 50(4):563\u2013575","journal-title":"Headache"},{"issue":"8","key":"2350_CR50","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2165\/11590370-000000000-00000","volume":"34","author":"B K\u00e4ll\u00e9n","year":"2011","unstructured":"K\u00e4ll\u00e9n B, Nilsson E, Otterblad Olausson P (2011) Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf 34(8):691\u2013703","journal-title":"Drug Saf"},{"issue":"9","key":"2350_CR51","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s10654-013-9831-x","volume":"28","author":"K Nezvalov\u00e1-Henriksen","year":"2013","unstructured":"Nezvalov\u00e1-Henriksen K, Spigset O, Nordeng H (2013) Triptan safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 28(9):759\u2013769","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"2350_CR52","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/ppe.12253","volume":"30","author":"ME Wood","year":"2016","unstructured":"Wood ME, Lapane K, Frazier JA, Ystrom E, Mick EO, Nordeng H (2016) Prenatal triptan exposure and Internalising and externalising behaviour Problems in 3-year-old children: results from the Norwegian mother and child cohort study. Paediatr Perinat Epidemiol 30(2):190\u2013200","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"3","key":"2350_CR53","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/ppe.12461","volume":"32","author":"GE Harris","year":"2018","unstructured":"Harris GE, Wood M, Ystrom E, Nordeng H (2018) Prenatal triptan exposure and neurodevelopmental outcomes in 5-year-old children: follow-up from the Norwegian mother and child cohort study. Paediatr Perinat Epidemiol 32(3):247\u2013255","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"6","key":"2350_CR54","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1177\/0333102417724152","volume":"38","author":"K Spielmann","year":"2018","unstructured":"Spielmann K, Kayser A, Beck E, Meister R, Schaefer C (2018) Pregnancy outcome after anti-migraine triptan use: a prospective observational cohort study. Cephalalgia 38(6):1081\u20131092","journal-title":"Cephalalgia"},{"key":"2350_CR55","doi-asserted-by":"crossref","unstructured":"Harris GM, Wood M, Ystrom E, Nordeng H (2022) Association of maternal use of triptans during pregnancy with risk of attention-deficit\/hyperactivity disorder in offspring. JAMA Netw Open 5(6):e2215333","DOI":"10.1001\/jamanetworkopen.2022.15333"},{"issue":"1","key":"2350_CR56","doi-asserted-by":"publisher","first-page":"19302","DOI":"10.1038\/s41598-021-97092-y","volume":"11","author":"A B\u00e9rard","year":"2021","unstructured":"B\u00e9rard A, Strom S, Zhao JP, Kori S, Albrecht D (2021) Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes. Sci Rep 11(1):19302","journal-title":"Sci Rep"},{"issue":"4","key":"2350_CR57","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/head.12500","volume":"55","author":"A Marchenko","year":"2015","unstructured":"Marchenko A, Etwel F, Olutunfese O, Nickel C, Koren G, Nulman I (2015) Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. Headache 55(4):490\u2013501","journal-title":"Headache"},{"issue":"2","key":"2350_CR58","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s00415-021-10534-5","volume":"269","author":"DC Dudman","year":"2022","unstructured":"Dudman DC, Tauqeer F, Kaur M, Ritchey ME, Li H, Lopez-Leon S (2022) A systematic review and meta-analyses on the prevalence of pregnancy outcomes in migraine treated patients: a contribution from the IMI2 ConcePTION project. J Neurol 269(2):742\u2013749","journal-title":"J Neurol"},{"key":"2350_CR59","doi-asserted-by":"publisher","first-page":"1481378","DOI":"10.3389\/fphar.2024.1481378","volume":"15","author":"A B\u00e9rard","year":"2024","unstructured":"B\u00e9rard A, Strom S, Albrecht D, Kori S (2024) Anti-migraine medications safety during pregnancy in the US. Front Pharmacol 15:1481378","journal-title":"Front Pharmacol"},{"issue":"7","key":"2350_CR60","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1177\/0333102420983292","volume":"41","author":"R Noseda","year":"2021","unstructured":"Noseda R, Bedussi F, Gobbi C, Zecca C, Ceschi A (2021) Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database. Cephalalgia 41(7):789\u2013798","journal-title":"Cephalalgia"},{"issue":"4","key":"2350_CR61","doi-asserted-by":"publisher","first-page":"333102423115808","DOI":"10.1177\/03331024231158083","volume":"43","author":"R Noseda","year":"2023","unstructured":"Noseda R, Bedussi F, Gobbi C, Ceschi A, Zecca C (2023) Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: updated analysis in VigiBase\u00ae. Cephalalgia 43(4):3331024231158083","journal-title":"Cephalalgia"},{"issue":"1","key":"2350_CR62","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-024-01715-4","volume":"25","author":"R Noseda","year":"2024","unstructured":"Noseda R, Bedussi F, Gobbi C, Ceschi A, Zecca C (2024) Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase(\u00ae). J Headache Pain 25(1):10","journal-title":"J Headache Pain"},{"issue":"1","key":"2350_CR63","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s10194-020-01196-1","volume":"21","author":"HT Wong","year":"2020","unstructured":"Wong HT, Khalil M, Ahmed F (2020) OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients. J Headache Pain 21(1):129","journal-title":"J Headache Pain"},{"key":"2350_CR64","doi-asserted-by":"crossref","unstructured":"Brin MF, Kirby RS, Slavotinek A, Adams AM, Parker L, Ukah A et al (2023) Pregnancy outcomes in patients exposed to OnabotulinumtoxinA treatment: a cumulative 29-year safety update. Neurology 101(2):e103\u2013e13","DOI":"10.1212\/WNL.0000000000207375"},{"issue":"10","key":"2350_CR65","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1111\/head.15001","volume":"65","author":"L Smirnoff","year":"2025","unstructured":"Smirnoff L, Moskatel L, Shaw B, He Z, Peretz A (2025) A retrospective cohort study to evaluate the effectiveness and safety profile of occipital nerve blocks in the treatment of migraine during pregnancy. Headache 65(10):1727\u20131733","journal-title":"Headache"},{"issue":"3","key":"2350_CR66","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1365-2125.1996.tb00185.x","volume":"41","author":"RE Wojnar-Horton","year":"1996","unstructured":"Wojnar-Horton RE, Hackett LP, Yapp P, Dusci LJ, Paech M, Ilett KF (1996) Distribution and excretion of sumatriptan in human milk. Br J Clin Pharmacol 41(3):217\u2013221","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2350_CR67","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/bcpt.13579","volume":"128","author":"S Amundsen","year":"2021","unstructured":"Amundsen S, Nordeng H, Fuskev\u00e5g OM, Nordmo E, Sager G, Spigset O (2021) Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding. Basic Clin Pharmacol Toxicol 128(6):795\u2013804","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"2350_CR68","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1089\/bfm.2021.0250","volume":"17","author":"TE Baker","year":"2022","unstructured":"Baker TE, Croop R, Kamen L, Price P, Stock DA, Ivans A et al (2022) Human milk and plasma pharmacokinetics of single-dose rimegepant 75 mg in healthy lactating women. Breastfeed Med 17(3):277\u2013282","journal-title":"Breastfeed Med"},{"issue":"3","key":"2350_CR69","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s13760-023-02190-5","volume":"123","author":"S Guerzoni","year":"2023","unstructured":"Guerzoni S, Baraldi C, Brovia D, Cainazzo MM, Castro FL, Pani L (2023) Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study. Acta Neurol Belg 123(3):1039\u20131047","journal-title":"Acta Neurol Belg"},{"issue":"11","key":"2350_CR70","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/14737175.2024.2403576","volume":"24","author":"AA Argyriou","year":"2024","unstructured":"Argyriou AA, Dermitzakis EV, Xiromerisiou G, Rikos D, Rallis D, Soldatos P et al (2024) Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry. Expert Rev Neurother 24(11):1119\u20131126","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"2350_CR71","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1046\/j.1468-2982.1997.1706662.x","volume":"17","author":"L Mets\u00e4honkala","year":"1997","unstructured":"Mets\u00e4honkala L, Sillanp\u00e4\u00e4 M, Tuominen J (1997) Outcome of early school-age migraine. Cephalalgia 17(6):662\u2013665","journal-title":"Cephalalgia"},{"issue":"4","key":"2350_CR72","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1046\/j.1468-2982.1997.1704488.x","volume":"17","author":"B Bille","year":"1997","unstructured":"Bille B (1997) A 40-year follow-up of school children with migraine. Cephalalgia 17(4):488\u2013491; discussion 7","journal-title":"Cephalalgia"},{"issue":"5","key":"2350_CR73","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1468-2982.2004.00680.x","volume":"24","author":"JA Zwart","year":"2004","unstructured":"Zwart JA, Dyb G, Holmen TL, Stovner LJ, Sand T (2004) The prevalence of migraine and tension-type headaches among adolescents in Norway. The nord-tr\u00f8ndelag health study (head-HUNT-Youth), a large population-based epidemiological study. Cephalalgia 24(5):373\u2013379","journal-title":"Cephalalgia"},{"issue":"3","key":"2350_CR74","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejpn.2006.11.010","volume":"11","author":"M Milovanovi\u0107","year":"2007","unstructured":"Milovanovi\u0107 M, Jarebinski M, Martinovi\u0107 Z (2007) Prevalence of primary headaches in children from Belgrade, Serbia. Eur J Paediatr Neurol 11(3):136\u2013141","journal-title":"Eur J Paediatr Neurol"},{"issue":"9","key":"2350_CR75","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/j.1468-2982.2008.01827.x","volume":"29","author":"S Slater","year":"2009","unstructured":"Slater S, Crawford MJ, Kabbouche MA, LeCates SL, Cherney S, Vaughan P et al (2009) Effects of gender and age on paediatric headache. Cephalalgia 29(9):969\u2013973","journal-title":"Cephalalgia"},{"issue":"6","key":"2350_CR76","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/0333102417727536","volume":"38","author":"M Sillanp\u00e4\u00e4","year":"2018","unstructured":"Sillanp\u00e4\u00e4 M, Saarinen MM (2018) Long term outcome of childhood onset headache: a prospective community study. Cephalalgia 38(6):1159\u20131166","journal-title":"Cephalalgia"},{"issue":"10","key":"2350_CR77","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/oxfordjournals.aje.a116014","volume":"134","author":"WF Stewart","year":"1991","unstructured":"Stewart WF, Linet MS, Celentano DD, Van Natta M, Ziegler D (1991) Age- and sex-specific incidence rates of migraine with and without visual aura. Am J Epidemiol 134(10):1111\u20131120","journal-title":"Am J Epidemiol"},{"issue":"6","key":"2350_CR78","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1526-4610.2011.01908.x","volume":"51","author":"S Gupta","year":"2011","unstructured":"Gupta S, McCarson KE, Welch KM, Berman NE (2011) Mechanisms of pain modulation by sex hormones in migraine. Headache 51(6):905\u2013922","journal-title":"Headache"},{"key":"2350_CR79","unstructured":"Ga\u00dfmann J, Barke A, van Gessel H, Kr\u00f6ner-Herwig B (2012) Sex-specific predictor analyses for the incidence of recurrent headaches in German schoolchildren. Psychosoc Med 9:Doc03"},{"issue":"14","key":"2350_CR80","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1177\/0333102415575723","volume":"35","author":"KG Vetvik","year":"2015","unstructured":"Vetvik KG, Benth J, MacGregor EA, Lundqvist C, Russell MB (2015) Menstrual versus non-menstrual attacks of migraine without aura in women with and without menstrual migraine. Cephalalgia 35(14):1261\u20131268","journal-title":"Cephalalgia"},{"issue":"4","key":"2350_CR81","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S1474-4422(20)30482-8","volume":"20","author":"KG Vetvik","year":"2021","unstructured":"Vetvik KG, MacGregor EA (2021) Menstrual migraine: a distinct disorder needing greater recognition. Lancet Neurol 20(4):304\u2013315","journal-title":"The Lancet Neurol"},{"issue":"6","key":"2350_CR82","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S1474-4422(04)00768-9","volume":"3","author":"EA MacGregor","year":"2004","unstructured":"MacGregor EA (2004) Oestrogen and attacks of migraine with and without aura. Lancet Neurol 3(6):354\u2013361","journal-title":"The Lancet Neurol"},{"issue":"12","key":"2350_CR83","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1212\/01.wnl.0000233888.18228.19","volume":"67","author":"EA MacGregor","year":"2006","unstructured":"MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A (2006) Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 67(12):2154\u20132158","journal-title":"Neurology"},{"issue":"3","key":"2350_CR84","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1212\/01.WNL.0000130338.62037.CC","volume":"63","author":"T Pringsheim","year":"2004","unstructured":"Pringsheim T, Gooren L (2004) Migraine prevalence in male to female transsexuals on hormone therapy. Neurology 63(3):593\u2013594","journal-title":"Neurology"},{"issue":"4","key":"2350_CR85","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/ana.21779","volume":"66","author":"K Eikermann-Haerter","year":"2009","unstructured":"Eikermann-Haerter K, Baum MJ, Ferrari MD, van den Maagdenberg AM, Moskowitz MA, Ayata C (2009) Androgenic suppression of spreading depression in familial hemiplegic migraine type 1 mutant mice. Ann Neurol 66(4):564\u2013568","journal-title":"Ann Neurol"},{"key":"2350_CR86","doi-asserted-by":"crossref","unstructured":"van Oosterhout, WPJ, Schoonman GG, van Zwet Ew, Dekkers OM, Terwindt GM, MaassenVandenbrink A et al (2018) Female sex hormones in men with migraine. Neurology 91(4):e374\u2013e81","DOI":"10.1212\/WNL.0000000000005855"},{"key":"2350_CR87","doi-asserted-by":"publisher","first-page":"100171","DOI":"10.1016\/j.ynpai.2024.100171","volume":"16","author":"AJ Dourson","year":"2024","unstructured":"Dourson AJ, Darken RS, Baranski TJ, Gereau RW, Ross WT, Nahman-Averbuch H (2024) The role of androgens in migraine pathophysiology. Neurobiol Pain 16:100171","journal-title":"Neurobiol Pain"},{"issue":"9","key":"2350_CR88","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/0333102414559735","volume":"35","author":"H Bolay","year":"2015","unstructured":"Bolay H, Ozge A, Saginc P, Orekici G, Ulud\u00fcz D, Yal\u0131n O et al (2015) Gender influences headache characteristics with increasing age in migraine patients. Cephalalgia 35(9):792\u2013800","journal-title":"Cephalalgia"},{"issue":"1","key":"2350_CR89","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s10194-025-02083-3","volume":"26","author":"NS Bugge","year":"2025","unstructured":"Bugge NS, Vetvik KG, Alstadhaug KB, Braaten T (2025) Migraine through puberty and menopausal transition-data from the population-based Norwegian women and health study (NOWAC). J Headache Pain 26(1):145","journal-title":"J Headache Pain"},{"issue":"4","key":"2350_CR90","first-page":"1495","volume":"81","author":"N Santoro","year":"1996","unstructured":"Santoro N, Brown JR, Adel T, Skurnick JH (1996) Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 81(4):1495\u20131501","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2350_CR91","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ecl.2015.05.010","volume":"44","author":"JE Hall","year":"2015","unstructured":"Hall JE (2015) Endocrinology of the menopause. Endocrinol Metab Clin N Am 44(3):485\u2013496","journal-title":"Endocrinol Metab Clin N Am"},{"key":"2350_CR92","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.maturitas.2020.07.005","volume":"142","author":"EA MacGregor","year":"2020","unstructured":"MacGregor EA (2020) Menstrual and perimenopausal migraine: a narrative review. Maturitas 142:24\u201330","journal-title":"Maturitas"},{"issue":"7","key":"2350_CR93","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10194-012-0475-0","volume":"13","author":"N Karl\u0131","year":"2012","unstructured":"Karl\u0131 N, Baykan B, Erta\u015f M, Zarifo\u011flu M, Siva A, Saip S et al (2012) Impact of sex hormonal changes on tension-type headache and migraine: a cross-sectional population-based survey in 2, 600 women. J Headache Pain 13(7):557\u2013565","journal-title":"J Headache Pain"},{"key":"2350_CR94","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s10194-015-0503-y","volume":"16","author":"JM Pavlovi\u0107","year":"2015","unstructured":"Pavlovi\u0107 JM, Stewart WF, Bruce CA, Gorman JA, Sun H, Buse DC et al (2015) Burden of migraine related to menses: results from the AMPP study. J Headache Pain 16:24","journal-title":"J Headache Pain"},{"issue":"2","key":"2350_CR95","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/head.12763","volume":"56","author":"VT Martin","year":"2016","unstructured":"Martin VT, Pavlovic J, Fanning KM, Buse DC, Reed ML, Lipton RB (2016) Perimenopause and menopause are associated with high frequency headache in women with migraine: results of the American migraine prevalence and prevention study. Headache 56(2):292\u2013305","journal-title":"Headache"},{"issue":"2","key":"2350_CR96","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1258\/mi.2009.009022","volume":"15","author":"RE Nappi","year":"2009","unstructured":"Nappi RE, Sances G, Detaddei S, Ornati A, Chiovato L, Polatti F (2009) Hormonal management of migraine at menopause. Menopause Int 15(2):82\u201386","journal-title":"Menopause Int"},{"issue":"1","key":"2350_CR97","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-018-0896-5","volume":"19","author":"S Sacco","year":"2018","unstructured":"Sacco S, Merki-Feld GS, \u00c6gidius KL, Bitzer J, Canonico M, Gantenbein AR et al (2018) Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of contraception and reproductive Health (ESCRH). J Headache Pain 19(1):76","journal-title":"J Headache Pain"},{"key":"2350_CR98","doi-asserted-by":"crossref","unstructured":"Allais G, Castagnoli Gabellari I, De Lorenzo C, Mana O, Benedetto C (2011) Oral contraceptives in migraine therapy. Neurol Sci 32(Suppl, 1):S135\u20139","DOI":"10.1007\/s10072-011-0538-z"},{"issue":"8","key":"2350_CR99","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1161\/STROKEAHA.117.017132","volume":"48","author":"E L\u00f8kkegaard","year":"2017","unstructured":"L\u00f8kkegaard E, Nielsen LH, Keiding N (2017) Risk of Stroke with various types of menopausal hormone therapies: a National cohort study. Stroke 48(8):2266\u20132269","journal-title":"Stroke"},{"key":"2350_CR100","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2147\/NDT.S285863","volume":"17","author":"R Ornello","year":"2021","unstructured":"Ornello R, Caponnetto V, Frattale I, Sacco S (2021) Patterns of migraine in postmenopausal women: a systematic review. Neuropsychiatr Dis Treat 17:859\u2013871","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"2350_CR101","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.maturitas.2012.01.006","volume":"71","author":"R Glaser","year":"2012","unstructured":"Glaser R, Dimitrakakis C, Trimble N, Martin V (2012) Testosterone pellet implants and migraine headaches: a pilot study. Maturitas 71(4):385\u2013388","journal-title":"Maturitas"},{"issue":"4","key":"2350_CR102","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrneurol.2015.29","volume":"11","author":"S Amundsen","year":"2015","unstructured":"Amundsen S, Nordeng H, Nezvalov\u00e1-Henriksen K, Stovner LJ, Spigset O (2015) Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat Rev Neurol 11(4):209\u2013219","journal-title":"Nat Rev Neurol"},{"key":"2350_CR103","doi-asserted-by":"crossref","unstructured":"Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. Obstet Gynecol, 2022 139(5):944\u2013972","DOI":"10.1097\/AOG.0000000000004766"},{"issue":"2","key":"2350_CR104","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1046\/j.1526-4610.2001.111006171.x","volume":"41","author":"S Demirkaya","year":"2001","unstructured":"Demirkaya S, Vural O, Dora B, Top\u00e7uo\u011flu MA (2001) Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache 41(2):171\u2013177","journal-title":"Headache"},{"issue":"3","key":"2350_CR105","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/17512433.2023.2181157","volume":"16","author":"JA Spiteri","year":"2023","unstructured":"Spiteri JA, Camilleri G, Piccinni C, Sultana J (2023) Safety of drugs used for the treatment of migraine during pregnancy: a narrative review. Expert Rev Clin Pharmacol 16(3):207\u2013217","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"Suppl, 1","key":"2350_CR106","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10072-014-1744-2","volume":"35","author":"EA MacGregor","year":"2014","unstructured":"MacGregor EA (2014) Migraine in pregnancy and lactation. Neurol Sci 35(Suppl, 1):61\u201364","journal-title":"Neurol. Sci"},{"issue":"3","key":"2350_CR107","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/ar1957","volume":"8","author":"M \u00d8stensen","year":"2006","unstructured":"\u00d8stensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H et al (2006) Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 8(3):209","journal-title":"Arthritis Res Ther"},{"key":"2350_CR108","doi-asserted-by":"crossref","unstructured":"Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E et al (2013) Canadian Headache Society guideline: acute drug therapy for migraine headache. Can J Neurol Sci 40(5 Suppl 3):S1\u2013s80","DOI":"10.1017\/S0317167100118943"},{"issue":"5","key":"2350_CR109","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/AOG.0000000000001375","volume":"127","author":"LL Siminerio","year":"2016","unstructured":"Siminerio LL, Bodnar LM, Venkataramanan R, Caritis SN (2016) Ondansetron use in pregnancy. Obstet Gynecol 127(5):873\u2013877","journal-title":"Obstet Gynecol"},{"key":"2350_CR110","doi-asserted-by":"crossref","unstructured":"Russo A, Iannone LF, Orologio I, Rivi V, Boccalini A, Lo Castro F et al (2025) Safety of onabotulinumtoxin-A for chronic migraine during pregnancy and breastfeeding: a narrative review. Toxins (Basel) 17(4)","DOI":"10.3390\/toxins17040192"},{"issue":"8","key":"2350_CR111","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","volume":"48","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB (2008) Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48(8):1157\u20131168","journal-title":"Headache"},{"issue":"3","key":"2350_CR112","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40120-025-00720-2","volume":"14","author":"M Waliszewska-Pros\u00f3\u0142","year":"2025","unstructured":"Waliszewska-Pros\u00f3\u0142 M, Grandi G, Ornello R, Raffaelli B, Straburzy\u0144ski M, Tana C et al (2025) Menopause, perimenopause, and migraine: understanding the intersections and implications for treatment. Neurol Ther 14(3):665\u2013680","journal-title":"Neurol Ther"},{"issue":"1","key":"2350_CR113","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s10194-025-02189-8","volume":"26","author":"C Angerh\u00f6fer","year":"2025","unstructured":"Angerh\u00f6fer C, Hoehne CL, Ulrich M, Lange KS, Fitzek MP, Salim Y et al (2025) Sex-related disparities in migraine recognition and management: insights from a tertiary headache center cohort. J Headache Pain 26(1):225","journal-title":"J Headache Pain"},{"key":"2350_CR114","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/topiramate"},{"key":"2350_CR115","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/valproate-related-substances-0"},{"issue":"9","key":"2350_CR116","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14740338.2023.2247963","volume":"22","author":"W Wells-Gatnik","year":"2023","unstructured":"Wells-Gatnik W, Martelletti P (2023) Antiseizure medications as migraine preventatives: a call for action for a teratogenic and neurodevelopmental risk removal. Expert Opin Drug Saf 22(9):777\u2013781","journal-title":"Expert Opin Drug Saf"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02350-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02350-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02350-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:03:01Z","timestamp":1777377781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02350-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2350"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02350-x","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review protocol was registered in the PROSPERO database (registration number: CRD420251058438).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Protocol registration"}},{"value":"The authors had full access to all data and take full responsibility for the integrity and accuracy of the analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Independence statement"}},{"value":"Simone Braca reports, unrelated to this work, over the last 36\u2009months, personal compensation from Eli Lilly for oral presentations. Esme Ekizoglu received honoraria for lectures, presentations from Pfizer and Neutec. Francesco Casillo received honoraria for consulting activities from Abbvie. Marte-Helene Bjork is supported by public and competitive research funding sources, including the Research Council of Norway (NorHead Centre for Clinical Treatment Research, grant 328615) and the TrondMohn Foundation (SAFE ASM, grant TMF2024TMT03. She reports advisory board honoraria and\/or speaking honoraria from Pfizer, Jazz Pharmaceuticals, Angelini Pharma, AbbVie, Lundbeck, Organon, and Eisai. Her institution (University of Bergen and Haukeland University Hospital) and research group (BergenBrain) have received funding from valproate marketing authorization holders forpost-marketing drug safety studies, and from Lundbeck for an industry-financed phase IV study of eptinezumab, all unrelated to the current work. Stefanie Moreira has nothing to disclose. Anna K. Szewczyk has nothing to disclose. Annelies Van Dycke received honoraria for participation on advisory\/scientific boards and\/or given lectures for Abbvie, Allergan, Angelini Pharma, Lilly, Lundbeck, Neuraxpharm, Novartis, Organon, Pfizer and Teva. Derya Uluduz is employed by \u0130stanbul university Cerrahpa\u015fa school of medicine neurology department and is a consultant for Abbvie and Pfizer. Gianluca Coppola serves as Associate Editor of The Journal of Headache and Pain, Cephalalgia, Cephalalgia Reports, Frontiers in Neurology (Neurotechnology section), BMC Neurology (Pain section), Frontiers in Human Neuroscience (Brain Imaging and Stimulation section), Headache and Pain Research, Confinia Cephalalgica. He has received honoraria as a moderator from AbbVie, Pfizer, and Eli-Lilly, has received consulting fees from AbbVie, Eli-Lilly, and Pfizer, and has been the PI in trials sponsored byPfizer and AbbVie. He has received research grants from AbbVie. Christina Deligianni has received travel grants and honoraria from AstraZeneca, Merck & Co, Pfizer and Teva Pharmaceuticals and research grants from the International Headache Society and the Hellenic Neurology Society. Christian Lampl has received consulting fees and honoraria for lectures\/ presentations from AbbVie\/Allergan, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva. CL participated in clinical trials as the principal investigator for Eli Lilly. Erling Tronvik has received personal fees for lectures\/advisory boards: Novartis, Eli Lilly, Abbvie, TEVA, Roche, Lundbeck, Pfizer, Biogen, Organon. Consultant for and owner of stocks and IP in Man & Science. Stocks and IP in Nordic BrainTech. Stocks in Keimon Medical. Non-personal research grants from several sources, including Norwegian Research Council, KlinBeForsk, EU. Commissioned research (non-personal): Lundbeck. Faisal Amin has received personal fees for lecturing and\/or participation in advisory boards from AbbVie, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals; and research grants from the Lundbeck Foundation. Jan Versijpt received personal fees and non-financial support from Pfizer, Lilly, and Teva; personal fees from Novartis and Lundbeck; and grants and non-financial support from Allergan and AbbVie. Kristina Ryliskiene has received personal fees for lectures\/advisory boards: Novartis, Abbvie, TEVA, Lundbeck, Pfizer, Viatris, Berlin Chemie. Margarita Sanchez del Rio reports personal fees as Speaker from Teva, Pfizer, Eli Lilly, Lundbeck and Organon. Phil Holland reports honoraria for educational and advisory purposes from Allergan, Novartis, and Teva as well as research funding from Eli Lilly and Company, Amgen, and Cellgene\/Bristol Myers Squibb. Gisela Terwindt reports consultancy support from AbbVie, Lilly, Lundbeck, Novartis, Organon, Pfizer, Teva, and independent support from the European Community, Dutch Heart Foundation, Dutch Research Council, Dutch Brain Foundation, Dioraphte, and the Clayco foundation. Uwe Reuter has received institutional fees from Amgen, Abbvie, Lilly, Lundbeck, Novartis, Pfizer, Medscape, SandTeva, and research funding from Novartis. Antoinette MaassenVanDenBrink reports honoraria for advisory board and\/or lectures from Allergan\/Abbvie,Amgen\/Novartis, Eli Lilly, Organo, Pfizer, as well as research grants from Manistee, Pfizer, Satsuma, Teva and Tonix.\u00a0She received independent research support from the European Community and Dutch Research Council as well as the Netherlands Organisation for Health Research and Development. Raquel Gil-Gouveia reports honoraria for consultant and\/or advisory boards from Allergan\/ Abbvie, Astra Zeneca,Almirall, Bial, Biogen, Bristol-Myers Squibb, CMBE, FLOAT, Lilly, Lundbeck, Merk, Novartis, Novo Nordisk, Organon, Pfizer, Roche, Sanofi, Tecnifar, and Teva; research funding from Funda\u00e7\u00e3o Ci\u00eancia Tecnologia (Project 29675,MigN2Treat, 02\/SAICT\/2017); Learning-Health, Luz Sa\u00fade (LiON, Luz Innovation on Neurosciences); Novartis-Sociedade Portuguesa de Cefaleias; Bolsa \u2013Projecto Centro de Investiga\u00e7\u00e3o Interdisciplinar em Sa\u00fade, and UCP.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}